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Background: The BRAF inhibitor, vemurafenib, has recently been approved for the treatment of metastatic
melanoma in patients harboring BRAFV600 mutations. Currently, dual BRAF and MEK inhibition are ongoing in
clinical trials with the goal of overcoming the acquired resistance that has unfortunately developed in some
vemurafenib patients. FDG-PET measures of metabolic activity are increasingly employed as a pharmacodynamic
biomarker for guiding single-agent or combination therapies by gauging initial drug response and monitoring
disease progression. However, since tumors are inherently heterogeneous, investigating the effects of BRAF and
MEK inhibition on FDG uptake in a panel of different melanomas could help interpret imaging outcomes.
Methods: 18 F-FDG uptake was measured in vitro in cells with wild-type and mutant (V600) BRAF, and in melanoma
cells with an acquired resistance to vemurafenib. We treated the cells with vemurafenib alone or in combination
with MEK inhibitor GDC-0973. PET imaging was used in mice to measure FDG uptake in A375 melanoma xenografts
and in A375 R1, a vemurafenib-resistant derivative. Histological and biochemical studies of glucose transporters, the
MAPK and glycolytic pathways were also undertaken.
Results: We demonstrate that vemurafenib is equally effective at reducing FDG uptake in cell lines harboring either
heterozygous or homozygous BRAFV600 but ineffective in cells with acquired resistance or having WT BRAF status.
However, combination with GDC-0973 results in a highly significant increase of efficacy and inhibition of FDG uptake
across all twenty lines. Drug-induced changes in FDG uptake were associated with altered levels of membrane GLUT-1,
and cell lines harboring RAS mutations displayed enhanced FDG uptake upon exposure to vemurafenib. Interestingly,
we found that vemurafenib treatment in mice bearing drug-resistant A375 xenografts also induced increased FDG
tumor uptake, accompanied by increases in Hif-1α, Sp1 and Ksr protein levels. Vemurafenib and GDC-0973
combination efficacy was associated with decreased levels of hexokinase II, c-RAF, Ksr and p-MEK protein.
Conclusions: We have demonstrated that 18 F-FDG-PET imaging reflects vemurafenib and GDC-0973 action across a
wide range of metastatic melanomas. A delayed post-treatment increase in tumor FDG uptake should be considered
carefully as it may well be an indication of acquired drug resistance.
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Melanoma is the deadliest of all skin cancers, and its in-
cidence has been steadily increasing over the past few
decades, especially in Caucasians [1]. Advanced melan-
oma patients have an 8-month median time of survival,
a figure that has improved little in the past decades des-
pite enormous research efforts [2]. This, however, is be-
ginning to change as personalized medicines targeting
the most commonly mutated oncogenes are being evalu-
ated in clinical trials. Vemurafenib is such an example
and is an orally available ATP competitive inhibitor of
the kinase domain within the BRAF oncogene [3]. BRAF
is mutated in more than 50% of all melanomas, with
BRAFV600E being the predominant mutation, increasing
the protein's kinase activity and, thereby, driving down-
stream cellular proliferation through the MAPK pathway
[4]. BRAFV600K/R mutations have also been reported to
occur in melanoma but seem to be very rare and found
mostly in other types of cancer [5].
Vemurafenib has shown impressive results in clinical
trials of patients with BRAFV600E mutations, resulting in
almost complete tumor regression and increasing pro-
gression free survival by 7 months and has gained FDA
approval [6]. However, two issues remain: tumors can
become resistant to vemurafenib and regrow over time,
and keratinocytes predisposed with mutated HRAS be-
come highly proliferative due to paradoxical activation
of the MAPK pathway, thereby, resulting in the develop-
ment of squamous cell carcinomas in some patients
[7,8]. It has recently been shown that the NRAS gene is
highly susceptible to mutation upon continuous vemura-
fenib exposure in pre-clinical studies; mutations in
MEK, itself, have also been reported [9-11]. Inhibition of
BRAF combined with MEK should have the potential to
address both outstanding issues, since MEK is a com-
mon downstream component of RAF and RAS signaling
[12,13]. Evidence of positive results from dual BRAF and
MEK inhibition in clinical trials is starting to emerge
(vemurafenib and GDC-0973 currently in phase II), and
effective evaluation of these drugs is important [14,15].
Positron emission tomography (PET) imaging using 2-
deoxy-2-[fluorine-18]-D-glucose integrated with com-
puted tomography (18 F-FDG-PET/CT) is a powerful
tool in oncology imaging[16,17]. Sensitive detection is
facilitated by the high metabolic demands of hyper-pro-
liferating cells driving an increase of glucose uptake [18].
18 F-FDG-PET/CT is primarily used in the clinic to stage
and restage malignancies (determine tumor burden,
evaluate drug efficacy) and to identify unknown metastases
across a wide range of cancer types. In melanoma, it is ap-
plied in advanced and recurrent stages of the disease
(American Joint Committee on Cancer stages III and IV)
where it offers unparalleled levels of sensitivity and specifi-
city relative to other techniques [19,20]. Despite thestrengths of PET imaging, its clinical utility (i.e., its ability
to inform patient management) depends strongly on the
clinical setting due to differences among tumor types (com-
position, mutation status and glucose avidity) and a treat-
ment's properties in altering tumor metabolism [21].
In order to guide the use of FDG-PET in the clinical de-
velopment of novel anti-cancer therapeutics and further
understand drug-tumor-imaging relationships, we ran a
series of cell-based 18 F-FDG uptake assays in vitro. These
employed a panel of melanoma cell lines and a robotic
screening platform that allows for precise, reproducible,
automated handling of the radioactive materials and subse-
quent optical and radioactivity readouts. We used these
assays to assess the effects of MEK and RAF inhibition on
FDG uptake across a wide range of melanomas, including
the clinically relevant vemurafenib drug-resistant A375R
lines with the expectation of recapitulating the responses
seen in solid tumors with FDG-PET imaging.
Methods
Drug treatment and 18 F-FDG cell screening
All human cell lines were obtained from a standardized
and curated in-house cell inventory (gCell; A375R1, R3
lines generated by Su et al. [10]) and grown in media ei-
ther Dulbecco's modified eagle's medium (DMEM) or
RPMI both supplemented with 10% of heat-inactivated
FBS and 2 mM L-Glutamine (GIBCO, Life Technologies
Corporation, NY, USA). Cells were plated on Cytostar-T
(PerkinElmer Inc., MA, USA) scintillating microplates at
a concentration of 25,000 cells/well on day 0. Vemurafe-
nib and GDC-0973 (Hoffmann-La Roche, Ltd., NJ, USA)
were dissolved in DMSO and added to media on day 1
and day 3. On day 4, 96 well plates containing cells were
loaded into our automated Oasis robotics system for
analysis: growth media was aspirated, cells washed once
with Krebs-Ringer buffer (Sigma-Aldrich Corporation,
St. Louis, MO, USA), then DMEM containing physio-
logical glucose (100 mg/dL) and 2.7 μCi of 2-Deoxy-2
18 F-FDG, and 5 μM Vybrant DyeCycle Ruby nuclear
stain (Invitrogen #V-10273, Invitrogen Ltd., Renfrew,
UK) was added per well and allowed to incubate for
1 hr. Plates were washed five times with Krebs-Ringer
buffer, fixed in 4% paraformaldehyde, sealed, radioactiv-
ity measured using a Microbeta2 Plate counter (Perki-
nElmer Inc., MA, USA), then ruby fluorescence
measured using a Synergy H4 Hybrid Multi-Mode
Microplate reader (BioTek Instruments, Inc., VT, USA).
Glucose transporter immunofluorescence
Cells were treated with drug as described above, then,
were fixed in 4% paraformaldehyde; permeabilized with
0.2% Triton; blocked in 5% fish gelatin; incubated with
either glucose transporter-1 (GLUT-1) antibody (Millipore
#07-1401, Millipore Co., Billerica, MA, USA) or glucose
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Plc, Cambridge, UK) overnight; washed in PBS; incubated
with secondary antibodies Alexa 488 (Invitrogen #A11008,
Invitrogen Ltd.) or Cy3 (Jackson ImmunoResearch #715-
165-150, Jackson ImmunoResearch Laboratories, Inc., PA,
USA) and Hoechst nuclear dye; washed in PBS; and then
analyzed by fluorescent microscopy.
18 F-FDG-PET/CT imaging
Athymic nude mice between 20-25 g in weight were sup-
plied by Harlan Laboratories Inc. (WA, USA) and
implanted in the right flank, subcutaneously with 5 million
A375 or A375R1 vemurafenib resistant in 100 μl HBSS.
When tumors reached a mean volume of 350-450 mm3,
mice were imaged with a Siemens Inveon microCT/PET
scanner (Siemens Medical Solutions, Inc., PA, USA) under
light sevoflurane anesthesia (approximately 3.5%) for re-
straint only. Body temperature was maintained at 37°C by
warm air flows under feedback control. The eyes were cov-
ered with ophthalmic ointment to prevent dehydration.
Dynamic PET scans lasted 30 min, and X-ray CT scans
were used for anatomical reference and attenuation correc-
tion. Blood glucose was measured pre- and post-scan; the
average was used in subsequent calculations. List mode
data were typically binned into 30 frames and recon-
structed into images with 128×128 in-plane voxels of
0.4 × 0.4 mm and 0.8 mm through-plane voxel thickness
using vendor-provided iterative OP-MAP implementation
with the beta hyper-parameter set to 0.05. Animals were
then randomized into three groups. Group 1 received
100 μl MCT vehicle, PO daily; group 2 received vemurafe-
nib 50 mg/kg PO BID; and group 3 received vemurafenib
50 mg/kg BID PO as well as 7.5 mg/kg GDC-0973 PO
daily for a total of 6 days and were imaged at baseline, day
3, and day 6 (n=3-7 per group) [22]. Inveon Acquisition
Workplace (Siemens Medical Solutions, Inc.) software was
used to draw regions of interest which were defined as vox-
els within the tumor having at least 50% of the intensity of
the brightest voxel within the tumor. This excludes the
hypointense (possibly necrotic) core tissue. Time-activity
data were exported to make Patlak-Gjedde plots [23] using
liver as a blood reference tissue [24] using the statistical
programming language R [25]. Ki is the tumor uptake rate
constant for FDG, and MRGlucMAX is the hypothetical
maximum glucose uptake capacity [26] defined as Ki × ([
blood glucose] +KM), where KM is a half-saturation
Michaelis constant set to 130 mg/dL; units =μmol/100 g/
min [26]. All animal handling studies were conducted
under the approval of Genentech's AALAC-accredited in-
stitutional animal care and use committee.
Western blot and histological analysis
Tumors were excised on day 7 after the trial, one day
after imaging, and frozen in liquid nitrogen fixed informalin. Frozen tissue was lysed with RIPA buffer and
then protein analyzed by western blot. Briefly, samples
were reduced with β-mercaptoethanol in SDS buffer,
heated to 95°C for 5 min, loaded into 8% Bis-Tris gels,
blocked with milk/TBS-T and probed for hexokinase I
and II (Santa Cruz #46695 and #6521, Santa Cruz Bio-
technology, Inc., CA, USA), Hif-1α (BD transduction
labs #610950, BD Biosciences, CA, USA), Sp1 (Cell Sig-
naling #5931, Cell Signaling Technology, Inc., MA,
USA), c-Raf and p-c-Raf (Millipore #04739 and #07-814,
Millipore, Co.), Ksr (Santa Cruz #9317), Mek and p-Mek
(Santa Cruz #6259 and Millipore #07-1474), Akt and p-
Akt (Cell Signaling #9272 S and #9271 S), c-Myc
(Sigma-Aldrich #C3956, Sigma-Aldrich Corporation)
and β Actin (Sigma-Aldrich #A5441). For histological
analysis, formalin-fixed tissue was transferred to 70%
ethanol, paraffin embedded, sectioned at 6 microns and
mounted on slides. Sections were then incubated with
target retrieval (Dako #S1700, Dako Inc., CA, USA) at
99°C for 20 min, peroxidase activity was quenched with
blocking solution (KPL #71-00-10, Kirkegaard & Perry
Laboratories, Inc., MD, USA), endogenous avidin and
biotin blocked (Vector Labs #SP-2001, Vector Labora-
tories, Inc., CA, USA) and endogenous immunoglobulins
blocked with 10% normal goat serum in 3% BSA/PBS
for 30 min. Slides were then incubated with anti-GLUT-
1 (Lab Vision Thermo Scientific #RB-9052-P, Thermo
Fisher Scientific Inc., MI, USA) for 1 hr, incubated with
biotinylated goat anti-rabbit IgG H+L (Vector Labs
#PK6100) for 30 min, incubated with ABC Elite Reagent
(Vector Labs #PK6100), and finally developed with
metal-enhanced DAB (Thermo Scientific #34065).
Results
In vitro 18 F-FDG uptake demonstrates vemurafenib
BRAFV600E selectivity as well as striking MEK potentiation
18 F-FDG uptake was evaluated in a panel of 19 melan-
oma cells, as well as the HCT 116 colorectal line, that
had been treated with BRAF inhibitor vemurafenib
alone, or in combination with MEK inhibitor GDC-0973
for a total of 3 days (Figure 1A). Vemurafenib was highly
selective in reducing total FDG uptake within cell lines
harboring one or two copies of mutant V600E BRAF al-
lele but completely ineffective in BRAF WT lines as well
as A375R1 and R3 vemurafenib-resistant cell lines.
Coadministration with GDC-0973 resulted in significant
decreases in 18 F-FDG uptake across almost all cell lines,
independent of mutation status; the combination treat-
ment strikingly overcame the A375R1 and R3 cell lines
lack of response to vemurafenib alone. Similar IC50
values were found between total FDG uptake [Additional
file 1 Figure S1A] and cell normalized FDG uptake
(Figure 1A), indicating that the drug effects primarily
induced changes in glucose transport and trapping
Figure 1 BRAF and MEK inhibition of FDG uptake. BRAF
inhibition reduces FDG uptake associated with presence of
BRAFV600E mutations, while coadministration of MEK inhibitor
broadly increases the effect. (A) A panel of melanoma cell lines that
were homozygous null; heterozygous or homozygous positive for
BRAFV600 mutations were treated with drug for 3 days, and FDG
uptake was assessed (Asterisk, lines with increased FDG uptake from
vemurafenib treatment). (B) Cell lines with both BRAFV600E and RAS
mutation were most susceptible to increased FDG uptake. Standard
error of the mean shown, n= 4/group.
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HS294T and RPMI-7951 melanomas, in which FDG re-
sponse was induced by cell death rather than glucose
metabolism; this was supported by the observation that
vemurafenib and GDC-0973 were unable to induce
changes in GLUT-1 at the membrane [Additional file 2:
Figure S2].
Vemurafenib induces increased 18 F-FDG uptake in BRAF
WT-RAS mutants
Vemurafenib treatment was found to induce a 15% to
30% increase in FDG uptake in WT BRAF/RAS mutants
(IPC-298 s, MEL-JUSO, SK-Mel-30 and HCT116) (Fig-
ure 1B). Comparison of total and cell-normalized values
showed that the increase in FDG uptake was in part dueto a proliferative effect induced by vemurafenib [Add-
itional file 1: Figure S1B]. PET imaging experiments sup-
port this notion of continuous BRAF inhibition leading
to an enhanced proliferative and metabolic response, as
has previously been demonstrated in vivo treating
HCT116 tumors with the BRAF inhibitor GDC-0879
[Additional file 3: Figure S3] [27].
Glucose transporter-1 membrane presence parallels
vemurafenib and MEK-induced effects on FDG uptake
Immunofluorescent staining for GLUT-1 and GLUT-3
showed that GLUT-1 was the major transporter present
across the panel of 20 in vitro cell lines. GLUT-3, a sec-
ondary glucose transporter in melanomas, displayed no
observable staining, suggesting that increased levels may
only be detectable in some patient biopsies and cells
transfected with high levels of the protein (GLUT-3
positive staining control; Additional file 4: Figure S4)
[28]. Furthermore, GLUT-1 mRNA expression levels are
significantly higher than GLUT-3 in most cancers, in-
cluding melanoma, and appear to be the dominant pro-
tein in the process of FDG uptake (glucose transport)
and trapping (hexokinase II) [Additional file 5: Figure
S5]. The relative levels of GLUT-1 on the cellular mem-
brane directly corresponded with the observed drug-
induced changes on intracellular FDG uptake that was
previously shown (Figure 2).
Vemurafenib treatment resulted in decreased levels of
GLUT-1 on the cellular membrane across all BRAFV600E
lines in a dose-dependent manner (with the exception of
HS294T and RPMI-7951; Additional file 3: Figure S3).
Coadministration of the MEK inhibitor GDC-0973 sig-
nificantly increased these effects and also overcame
tumor vemurafenib resistance. The increased FDG up-
take that is induced by vemurafenib treatment for the
wild-type BRAF/RAS mutants could be attributed to the
dose-dependent increases of GLUT-1 levels at the
plasma membrane (Figure 2).
FDG-PET is effective for monitoring BRAFi/MEKi efficacy
and can be used to gauge vemurafenib-induced drug
resistance
Vemurafenib treatment induced significant reductions in
the dynamic FDG uptake parameters Ki and MRGLUC
MAX
in A375 xenografts over the course of 6 days (Figure 3).
Similar to earlier in vitro results, the addition of GDC-
0973 also significantly improved FDG response. Both treat-
ments also lead to reductions in tumor volumes and did
not result in any significant changes in body weight.
Vemurafenib treatment of the resistant A375R1 tumors
resulted in a significant increase in dynamic FDG uptake
over the period of drug treatment, indicating the effect as a
sign of vemurafenib drug resistance. An increase in FDG
uptake was also observed with 6 days of vemurafenib
Figure 2 BRAF and MEK modulation of GLUT-1. BRAF and MEK inhibition results in changes in the amount of GLUT-1 at the cellular
membrane associated with levels of FDG uptake. Immunofluorescent staining was performed for GLUT-1 (green) and nuclei (blue) on all panels of
cells from Figure 1, which had been treated with drug for 3 days. (A) A375s, (B) resistant clone A375R1, (C) SK-Mel-30 melanomas and (D) HCT
116 colorectal cells.
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addition of GDC-0973 overcame drug resistance as
demonstrated by reductions in Ki, MRGLUC
MAX and
tumor volume. Histological analysis of the tumor xeno-
grafts demonstrated parallels between GLUT-1 membrane
intensity and FDG uptake, and also confirmed the signifi-
cant efficacy enhancement with the addition of GDC-0973
(Figure 4). Increases in GLUT-1 levels in vemurafenib-trea-
ted A375R1s were apparent using a more sensitiveimmunofluorescent histological approach [Additional file
6: Figure S6B].
Vemurafenib-resistant A375 R1 tumors exhibit increased
baseline Hif-1α, whose levels are further increased by
vemurafenib treatment along with Sp1 and Ksr, while
FDG-PET efficacy is correlated with decreases in glucose
metabolism and MAPK signaling. Following the last day of
PET imaging, tumors were excised. Proteins involved with
the FDG uptake as well as the MAPK and AKT pathways
Figure 3 FDG-PET imaging. FDG-PET imaging is effective for monitoring vemurafenib and GDC-0973 combination drug action in BRAFV600E mutant
and resistant xenografts. (A) A375- and (B) A375 R1-resistant KRAS mutant melanomas were implanted in athymic nude mice and were administered
vehicle, vemurafenib (50 mg/kg BID) or vemurafenib (50 mg/kg BID) and GDC-0973 (7.5 mg/kg QD). Dynamic FDG-PET imaging was performed at
baseline, day 3 and day 6 after treatment. A reduction in Ki and MRGluc
MAX was induced on day 6 of imaging by both vemurafenib and 0973
combination treatment (Student's t test showing standard error of the mean A375: MRGlucMax− vemuraf; *p=0.02, combination; **p=0.01,
Ki− vemuraf; *p=0.02, combination; **p= 0.001, tumor volume; ***p=0.001. A375R1: MRGluc
Max− vemuraf; *p=0.04, tumor volume; ***p=0.001).
White arrow points at the tumor.
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changes were found in hexokinase I between all groups;
however, tumor predominant hexokinase II was decreased
in both lines when treated with the drug combination. Hif-
1α was faintly present in A375s but significantly expressed
in A375R1s, and further induced by vemurafenib treatment
in the resistant line but countered with combinatorial
MEK inhibition. Sp1 levels were reduced by combination
treatment in the A375 line, and reduced levels of vemura-
fenib induced Sp1 in the resistant line. c-RAF, p-MEK and
Ksr protein levels were all reduced in both lines when trea-
ted with the RAF/MEK inhibitor drug combination. Drug
combination also caused greater inhibitor effects onhexokinase II, CRAF and p-MEK expression in the A375
tumors than the A375 R1s with the exception in p-AKT
that was only induced in the resistant line.
Discussion
Vemurafenib is a personalized medicine that targets the
product of a genetic mutation whose presence is required
for therapeutic efficacy. The companion diagnostic used
in patients in order to identify this mutation is the cobasW
4800 (F. Hoffmann-La Roche Ltd., USA) BRAFV600 test,
which is a PCR-based procedure used on biopsy tissue iso-
lated from a single melanoma lesion. A limitation with
this approach is that advanced melanoma patients have
Figure 4 Immunohistochemical staining of GLUT-1. Vemurafenib treatment induces decreases in both total and membrane GLUT-1 staining in A375
tumors but not in the resistant A375R1 line. Immunohistochemical staining for GLUT-1 in (A) A375 tumor xenografts and (B) A375R1-resistant xenografts.
Baudy et al. EJNMMI Research 2012, 2:22 Page 7 of 10
http://www.ejnmmires.com/content/2/1/22dozens to hundreds of tumor lesions, which are likely to
be genetically heterogeneous; therefore, a single biopsy
does not assure that all lesions contain BRAFV600 muta-
tions [29]. 18 F-FDG-PET imaging could perhaps discrim-
inate between these populations relatively early in the
course of treatment based on the effects of vemurafenib
on the FDG-PET images. Importantly, our studies also
suggest that an increase in FDG uptake observed in a spe-
cific tumor lesion from a patient on vemurafenib treat-
ment could well be indicative of acquired drug resistance
(Figure 3). If confirmed clinically, these findings could
help inform decisions regarding discontinuation or
changes in treatment, particularly since the increased
FDG uptake is driven by metabolic changes that accelerate
tumor growth rather than simply resulting in a lack of any
response. We note that this phenomenon is a distinct
metabolic adaption that differs from the well-known ‘flare’phenomena observed by FDG-PET during the initial
growth of tumors and ‘inflammatory flare’, which occurs
during infection or T-cell activation [30].
We observed that the addition of a MEK inhibitor coun-
tered the vemurafenib-induced increases of glycolytic ac-
tivity in WT-BRAFV600-Ras mutant populations. This is
relevant since these populations may be present in sites
not identified by the cobasW 4800 (F. Hoffmann-La Roche
Ltd.) BRAFV600 test and would otherwise contribute to
added cancerous growth (Figure 1) [13]. Additional advan-
tages of combined RAF and MEK inhibition were the
broader range of efficacy exhibited across melanoma cell
lines and the ability to overcome vemurafenib drug resist-
ance. While single GDC-0973 efficacy was not studied
here, it is important to note that MEK inhibitors generally
have higher toxicity profiles; therefore, maximizing the
dose of targeted therapeutic vemurafenib is advantageous.
Figure 5 Effects of BRAF and MEK on pathway proteins.
Vemurafenib treatment induced reductions of the MAPK pathway in
A375s but caused increases in MAPK and glucose metabolism/
signaling resistant A375 R1s. Western blot analysis of PET-imaged
tumors that had been treated with drug for 6 days is shown.
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mutations that have acquired additional copy numbers of
the BRAF gene [31,32].
The BRAFV600E mutation has been reported to predict
sensitivity to MEK inhibition, and RAS mutants have been
found to be more resistant to treatment [33]. We find that
the BRAFV600E mutation was only slightly predictive of
GDC-0973 response and only with regards to total FDG
uptake rather than cell-normalized values; our findings are
in agreement with the finding that RAS mutant cell lines
have heightened resistance to MEK inhibition (Figure 1B;
Additional file 1: Figure S1B). Other BRAFV600 cell lines
have previously been shown to have high 3H-FDG avidity
relative WT lines, and vemurafenib has been shown to ef-
fectively reduce FDG uptake in a M248 BRAFV600E xeno-
graft mouse model [34]. We expand on these findings by
demonstrating a clear BRAFV600 vemurafenib dose-re-
sponse relationship by 18 F-FDG in a larger panel of dis-
tinct melanoma cell lines including the especially clinically
relevant A375R1/R3 lines and validate effective in vivo
FDG-PET response in A375 BRAFV600E models.
GLUT-1 is the predominant glucose transporter facilitat-
ing enhanced glucose uptake in many tumor types and has
been shown to be upregulated in isogenic cell lines when
BRAFV600E and KRASG13D mutations are introduced [35-
38]. We did not observe any significant increases in base-
line FDG uptake with the introduction of the RASK117N
mutation alone in the A375R1 line relative to parentalA375. We did, however, observe that in A375 R1 tumors,
vermurafenib provoked the MAPK pathway via compensa-
tory increases in c-RAF and Ksr; this likely lead to induc-
tion of Hif-1α and Sp1 transcription factors (independent
of c-Myc), resulting in increased levels of hexokinase II,
membrane GLUT-1 and, thereby, subsequent FDG uptake
[39,40] (Figures 3B, 4B and 5; Additional file 6: Figure S6).
Further evidence of compensatory increases in MAPK acti-
vation/growth by RAF inhibition was observed in treated
BRAF-WT, RAS mutant HCT116 xenografts that dis-
played significantly increased tumor volumes and FDG up-
take [Additional file 3: Figure S3].Conclusions
Acquired drug resistance may arise in patients taking
vemurafenib for extended periods. Ongoing clinical trials
combining vemurafenib with GDC-0973 seek to overcome
this. Our study shows that 18 F-FDG can be a sensitive phar-
macodynamic biomarker not only for assessing vemurafenib
efficacy but also for acquired resistance. This could be a
valuable early indicator of tumor rebound. Mechanistically,
we find that this resistance is associated with the induction
of membrane GLUT-1, likely driven by glycolytic regulators
Hif-1α and Sp1. Furthermore, inhibition of MEK with
GDC-0973 can prevent this metabolic tumor resistance sig-
naling, and this too is recapitulated with FDG-PET imaging.Additional files
Additional file 1: Total FDG uptake IC50 values from Figure 1A and B
that have not been normalized to cell number.
Additional file 2: Vemurafenib, as well as GDC-0973 combination
treatments did not result in any apparent changes of GLUT-1 levels
(green) in RPMI-795 1 and HS294T melanomas.
Additional file 3: GDC-0879 BRAF inhibitor increase in FDG uptake and
tumor volume in vivo in HCT 116 colorectal (BRAF WT, RAS mutant)
tumor xenografts.
Additional file 4 GLUT-3 immunofluorescent staining in H1299 cells.
H1299 cells were transiently transfected with mock empty vector or
CMV-Glut3 vector for 3 days, then fixed and stained for GLUT-3.
Additional file 5: Genomic mRNA expression levels taken from an
integrated set of gene data from Entrez, Ensembl and Genentech
databases. Glucose transporters 1 and 3, and hexokinase II mRNA
expression levels are shown in normal and cancer tissues across a range
of tumor types.
Additional file 6: Six days of vemurafenib exposure results in increased
FDG uptake in A375R1 resistant cells in vitro and induces upregulation of
GLUT-1 in A375R1 xenograft sections. (A) Continuous treatment of 1nM
vemurafenib alone or in combination with 1nM GDC-0973 effects on
FDG uptake. Student's t test showing standard error of the mean.
**p< 0.01, ***p< 0.001 B. Vemurafenib induces increase in total
membrane GLUT-1 expression (green) in immunofluorescently stained
sections (blue = hoechst nuclear stain), shown at 4× magnification.Abbreviations
CT: Computed tomography; DMEM: Dulbecco's modified eagle's medium;
GLUT-1: Glucose transporter-1; GLUT-3: Glucose transporter-3; PET: Positron
emission tomography.
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